CYCC - Cyclacel Pharmaceuticals GAAP EPS of -$0.46 beats by $0.08 revenue of $0M
- Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q2 GAAP EPS of -$0.46 beats by $0.08 .
- Revenue of $0M.
- As of June 30, 2022, cash and cash equivalents totaled $29.1 million, compared to $36.6 million as of December 31, 2021.
For further details see:
Cyclacel Pharmaceuticals GAAP EPS of -$0.46 beats by $0.08, revenue of $0M